157 related articles for article (PubMed ID: 37394114)
21. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
Front Immunol; 2022; 13():969660. PubMed ID: 36059523
[TBL] [Abstract][Full Text] [Related]
22. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
[TBL] [Abstract][Full Text] [Related]
24. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed/refractory large B-cell lymphoma: findings from a German monocentric study.
Eigendorff F; Filimonova I; Scholl S; Sayer-Klink A; Rummler S; Kunert C; Pietschmann K; Wittig A; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2024 May; 150(5):224. PubMed ID: 38693452
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison.
Schuster SJ; Zhang J; Yang H; Agarwal A; Tang W; Martinez-Prieto M; Bollu V; Kuzan D; Maziarz RT; Kersten MJ
Leuk Lymphoma; 2022 Apr; 63(4):845-854. PubMed ID: 34978255
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV; David KA; Torka P; Hashmi H; Hess B; Barta SK; Romancik JT; Cohen JB; Annunzio K; Kittai AS; Reneau J; Zurko J; Nizamuddin IA; Winter JN; Gordon LI; Ma S; Patel R; Nastoupil L; Ahmed S; Karmali R
J Hematol Oncol; 2023 Nov; 16(1):111. PubMed ID: 37946255
[TBL] [Abstract][Full Text] [Related]
27. A Model to Estimate Cytokine Release Syndrome and Neurological Event Management Costs Associated With CAR T-Cell Therapy.
Badaracco J; Gitlin M; Keating SJ
Transplant Cell Ther; 2023 Jan; 29(1):59.e1-59.e6. PubMed ID: 36272529
[TBL] [Abstract][Full Text] [Related]
28. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.
Salles G; Schuster SJ; Dreyling M; Fischer L; Kuruvilla J; Patten PEM; von Tresckow B; Smith SM; Jiménez-Ubieto A; Davis KL; Anjos C; Chu J; Zhang J; Lobetti Bodoni C; Thieblemont C; Fowler NH; Dickinson M; Martínez-López J; Wang Y; Link BK
Blood Adv; 2022 Nov; 6(22):5835-5843. PubMed ID: 35973192
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.
Ying Z; Xie Y; Zheng W; Liu W; Lin N; Tu M; Wang X; Ping L; Deng L; Zhang C; Wu M; Feng F; Du T; Tang Y; Su F; Guo Z; Li J; Song Y; Zhu J
Bone Marrow Transplant; 2023 Mar; 58(3):288-294. PubMed ID: 36477110
[TBL] [Abstract][Full Text] [Related]
30. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
31. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A; Roddie C; Kirkwood AA; Tholouli E; Menne T; Patel A; Besley C; Chaganti S; Sanderson R; O'Reilly M; Norman J; Osborne W; Bloor A; Lugthart S; Malladi R; Patten PEM; Neill L; Martinez-Cibrian N; Kennedy H; Phillips EH; Jones C; Sharplin K; El-Sharkawi D; Latif AL; Mathew A; Uttenthal B; Stewart O; Marzolini MAV; Townsend W; Cwynarski K; Ardeshna K; Ardavan A; Robinson K; Pagliuca A; Collins GP; Johnson R; McMillan A
Br J Haematol; 2022 Aug; 198(3):492-502. PubMed ID: 35485402
[TBL] [Abstract][Full Text] [Related]
32. Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia.
McNerney KO; Moskop A; Winestone LE; Baggott C; Talano JA; Schiff D; Rossoff J; Modi A; Verneris MR; Laetsch TW; Schultz L
Transplant Cell Ther; 2024 Jan; 30(1):75.e1-75.e11. PubMed ID: 37816472
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma.
Steiner RE; Banchs J; Koutroumpakis E; Becnel M; Gutierrez C; Strati P; Pinnix CC; Feng L; Rondon G; Claussen C; Palaskas N; Karimzad K; Ahmed S; Neelapu SS; Shpall E; Wang M; Vega F; Westin J; Nastoupil LJ; Deswal A
Haematologica; 2022 Jul; 107(7):1555-1566. PubMed ID: 34758610
[TBL] [Abstract][Full Text] [Related]
34. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.
Yu W; Huang L; Mei H; Li Y; Niu T; Zou D; Liu Y; Zhang H; Liu P; Wu J; Wang Z; Li H; Cai Q; Mi JQ
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38802271
[TBL] [Abstract][Full Text] [Related]
35. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
Bücklein V; Perez A; Rejeski K; Iacoboni G; Jurinovic V; Holtick U; Penack O; Kharboutli S; Blumenberg V; Ackermann J; Frölich L; Johnson G; Patel K; Arciola B; Mhaskar R; Wood A; Schmidt C; Albanyan O; Gödel P; Hoster E; Bullinger L; Mackensen A; Locke F; von Bergwelt M; Barba P; Subklewe M; Jain MD
Hemasphere; 2023 Aug; 7(8):e907. PubMed ID: 37449196
[TBL] [Abstract][Full Text] [Related]
36. Predictors and Management of Relapse to Axicabtagene Ciloleucel in Patients with Aggressive B-cell Lymphoma.
Forero-Forero JV; Lengerke-Diaz PA; Moreno-Cortes E; Melody M; Rahman ZA; Rosenthal AC; Kharfan-Dabaja MA; Castro JE
Hematol Oncol Stem Cell Ther; 2023 Jan; 16(2):133-143. PubMed ID: 34562407
[TBL] [Abstract][Full Text] [Related]
37. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
[TBL] [Abstract][Full Text] [Related]
38. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement.
Yi D; Gergis M; Elgohary G; Hsu J; Yang Y; Bi X; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):66-72. PubMed ID: 36537908
[TBL] [Abstract][Full Text] [Related]
39. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Frank MJ; Hossain NM; Bukhari A; Dean E; Spiegel JY; Claire GK; Kirsch I; Jacob AP; Mullins CD; Lee LW; Kong KA; Craig J; Mackall CL; Rapoport AP; Jain MD; Dahiya S; Locke FL; Miklos DB
J Clin Oncol; 2021 Sep; 39(27):3034-3043. PubMed ID: 34133196
[TBL] [Abstract][Full Text] [Related]
40. Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel.
Fried S; Shouval R; Varda-Bloom N; Besser MJ; Yerushalmi R; Shem-Tov N; Danylesko I; Jacoby E; Teihman S; Itzhaki O; Fein JA; Kedmi M; Shimoni A; Nagler A; Avigdor A
Leuk Lymphoma; 2022 Dec; 63(14):3385-3393. PubMed ID: 36111694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
